Sort
85,873 grants matching “alzheimers”
The lipid amidase NAAA as a therapeutic target for Alzheimer's disease
$2,328,624Daniele Piomelli · University Of California-Irvine · RF1 · FY2020 · AG
Community Paramedicine
$2,328,172Manish N Shah · New York University School Of Medicine · U19 · FY2023 · AG
Alzheimer's Disease Research Center
$2,327,945Oscar L. Lopez · University Of Pittsburgh At Pittsburgh · P50 · FY2018 · AG
Open Drug Discovery Center for Alzheimer's Disease
$2,326,786Allan I Levey · Emory University · U54 · FY2022 · AG
Structural analysis of tau associated with parenchymal and vascular prion protein amyloidosis
$2,326,501Ruben Vidal · Indiana University Indianapolis · RF1 · FY2021 · AG
AGING BRAIN: VASCULATURE, ISCHEMIA, AND BEHAVIOR
$2,326,278University Of Southern California · P01 · FY2003 · AG
Phase II trial of GM-CSF/sargramostim in Alzheimer's Disease
$2,326,177Huntington Potter · University Of Colorado Denver · R01 · FY2022 · AG
Copy Number Variation Identification and Association Study on Alzheimer's Disease Whole Genome Sequencing Data
$2,325,638Wan-Ping Lee · University Of Pennsylvania · RF1 · FY2021 · AG
Uncovering stress-induced mechanisms of Tau pathology in Alzheimer's disease
$2,325,462Clarissa Leigh Waites · Columbia University Health Sciences · RF1 · FY2020 · AG
DEploying High ValuE LOngitudinal Population-Based dAta in Dementia Research (DEVELOP AD Research)
$2,325,044R. Sean Morrison · Icahn School Of Medicine At Mount Sinai · P01 · FY2024 · AG
Molecular signaling during development and maturation of the nervous system
$2,324,894David Talmage · National Institute Of Neurological Disorders And Stroke · ZIA · FY2025 · NS
Clinical trials to prevent Alzheimer's Disease in Down Syndrome
$2,324,837Michael S Rafii · University Of Southern California · R61 · FY2020 · AG
Implementation Science and Equity
$2,324,747Kimber P Richter · University Of Kansas Medical Center · P20 · FY2023 · GM
A Randomized Controlled Trial of Electroconvulsive Therapy plus Usual Care versus Simulated-ECT plus Usual Care for the Acute Management of Severe Agitation in Alzheimer's Dementia (ECT-AD)
$2,324,251Brent Peter Forester · Mclean Hospital · R01 · FY2021 · AG
Pro-inflammatory cytokine lowering anti-inflammatory drugs
$2,323,536Nigel H. Greig · National Institute On Aging · ZIA · FY2024 · AG
MOLECULAR PATHOGENESIS OF AGE-DEPENDENT CNS DEGENERATION
$2,323,439University Of California San Francisco · P01 · FY2003 · AG
Clinical trials to prevent Alzheimer's Disease in Down Syndrome
$2,323,427Michael S Rafii · University Of Southern California · R61 · FY2019 · AG
Glycogen synthase kinase 3 ligand discovery for Alzheimerâs disease
$2,323,421Steven H Liang · Emory University · RF1 · FY2023 · AG
Investigations of targets, mechanisms, and optimal delivery of therapeutic ketosis for functional longevity and treatment of Alzheimer's disease
$2,322,966Gino A Cortopassi · University Of California At Davis · P01 · FY2021 · AG
Longitudinal Relationships Among Sleep, Cognition and Alzheimer's Disease Biomarkers: Discerning Causal Associations, Mediators and Susceptibility
$2,322,513Susan S Redline · Brigham And Women'S Hospital · R01 · FY2023 · AG
Temporal Trends, Novel Imaging and Molecular Characterization of Preclinical and Clinical Alzheimer's Disease in the Framingham Cohorts
$2,322,345Sudha Seshadri · Boston University Medical Campus · R01 · FY2016 · AG
Open Drug Discovery Center for Alzheimer's Disease
$2,321,263Allan I Levey · Emory University · U54 · FY2019 · AG
Multidimensional mapping of vulnerable cell types in humanized Alzheimer's disease mouse models
$2,321,170Inma Cobos · Stanford University · R01 · FY2024 · AG
National Resource for Mass Spectrom of Biological Macromolecules
$2,320,963Brian T Chait · Rockefeller University · P41 · FY2013 · GM
Lifetime stressors and Alzheimer's Disease genetic variants and biomarkers in relation to cognitive decline among Black Women'sHealth Study participants.
$2,320,702Lynn Rosenberg · Boston University Medical Campus · R01 · FY2024 · AG